@article {Kennye000021, author = {S L Kenny and T D Shaw and D G Downey and J E Moore and J C Rendall and J S Elborn}, title = {Eradication of Pseudomonas aeruginosa in adults with cystic fibrosis}, volume = {1}, number = {1}, elocation-id = {e000021}, year = {2014}, doi = {10.1136/bmjresp-2014-000021}, publisher = {Archives of Disease in childhood}, abstract = {Background Eradication of new infection of Pseudomonas aeruginosa is an important intervention in managing cystic fibrosis (CF). Previous trials, studying predominantly under 18-year-olds, indicate that antibiotic eradication therapy (AET) has success rates of 62.8{\textendash}93.0\%. In this retrospective cohort study, we report the outcomes of AET in an adult population. Methods Adults with a confirmed diagnosis of CF and a first isolation of P aeruginosa were studied between 1999 and 2012. Choice of therapy, time to eradication and reinfection, and lung function (forced expiratory volume in 1 s (FEV1)) were determined. Results 20 patients (median age 27 years) isolated P aeruginosa during the study period. 10 patients were treated with oral ciprofloxacin (median duration 6 weeks) and nebulised colomycin (median duration 3 months). 7 patients were treated with intravenous antipseudomonal antibiotics (median duration 14 days). 2 patients received other combinations of oral and inhaled antipseudomonal therapy and one patient received no therapy. AET was successful in 15 cases who received antipseudomonal therapy (79\%). The median time to eradication was 1 month. The median time to reinfection with P aeruginosa was 43 months. There was no significant change in FEV1 after 12 months. Conclusions Aggressive AET of new infection of P aeruginosa in adults is successful in the majority of patients and has similar efficacy to the reported efficacy in paediatric populations.}, URL = {https://bmjopenrespres.bmj.com/content/1/1/e000021}, eprint = {https://bmjopenrespres.bmj.com/content/1/1/e000021.full.pdf}, journal = {BMJ Open Respiratory Research} }